| Evaluation and prognostic significance of circulating tumor cells in patients with non–small-cell lung cancer MG Krebs, R Sloane, L Priest, L Lancashire, JM Hou, A Greystoke, ... Journal of clinical oncology 29 (12), 1556-1563, 2011 | 1080 | 2011 |
| Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer JM Hou, MG Krebs, L Lancashire, R Sloane, A Backen, RK Swain, ... Journal of Clinical Oncology 30 (5), 525-532, 2012 | 1033 | 2012 |
| Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer CL Hodgkinson, CJ Morrow, Y Li, RL Metcalf, DG Rothwell, F Trapani, ... Nature medicine 20 (8), 897-903, 2014 | 843 | 2014 |
| Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy JM Hou, A Greystoke, L Lancashire, J Cummings, T Ward, R Board, ... The American journal of pathology 175 (2), 808-816, 2009 | 299 | 2009 |
| Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer RE Board, AM Wardley, JM Dixon, AC Armstrong, S Howell, L Renshaw, ... Breast cancer research and treatment 120, 461-467, 2010 | 238 | 2010 |
| Update on tubulin-binding agents G Attard, A Greystoke, S Kaye, J De Bono Pathologie Biologie 54 (2), 72-84, 2006 | 215 | 2006 |
| ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK … BC Cho, DW Kim, A Bearz, SA Laurie, M McKeage, G Borra, K Park, ... Journal of Thoracic Oncology 12 (9), 1357-1367, 2017 | 200 | 2017 |
| Biomarkers of apoptosis TH Ward, J Cummings, E Dean, A Greystoke, JM Hou, A Backen, ... British journal of cancer 99 (6), 841-846, 2008 | 162 | 2008 |
| Biomarker method validation in anticancer drug development J Cummings, TH Ward, A Greystoke, M Ranson, C Dive British journal of pharmacology 153 (4), 646-656, 2008 | 162 | 2008 |
| A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours OA Khan, M Gore, P Lorigan, J Stone, A Greystoke, W Burke, ... British journal of cancer 104 (5), 750-755, 2011 | 157 | 2011 |
| The National Lung Matrix Trial of personalized therapy in lung cancer G Middleton, P Fletcher, S Popat, J Savage, Y Summers, A Greystoke, ... Nature 583 (7818), 807-812, 2020 | 152 | 2020 |
| Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer RE Board, VS Williams, L Knight, J Shaw, A Greystoke, M Ranson, C Dive, ... Annals of the New York Academy of Sciences 1137 (1), 98-107, 2008 | 136 | 2008 |
| First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014 B Basu, E Dean, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, ... Clinical cancer research 21 (15), 3412-3419, 2015 | 132 | 2015 |
| Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis MJ Ahn, CH Chiu, Y Cheng, JY Han, SB Goldberg, A Greystoke, ... Journal of Thoracic Oncology 15 (4), 637-648, 2020 | 128 | 2020 |
| DNA methylation in circulating tumour DNA as a biomarker for cancer RE Board, L Knight, A Greystoke, FH Blackhall, A Hughes, C Dive, ... Biomarker Insights 2, 117727190700200003, 2007 | 95 | 2007 |
| Optimisation of circulating biomarkers of cell death for routine clinical use A Greystoke, J Cummings, T Ward, K Simpson, A Renehan, F Butt, ... Annals of oncology 19 (5), 990-995, 2008 | 86 | 2008 |
| A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours G Mak, JC Soria, SP Blagden, R Plummer, RA Fleming, N Nebot, J Zhang, ... British journal of cancer 120 (10), 975-981, 2019 | 78 | 2019 |
| Alternative splicing in lung cancer AO Coomer, F Black, A Greystoke, J Munkley, DJ Elliott Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1862 (11-12 …, 2019 | 77 | 2019 |
| A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer S Halford, GJ Veal, SR Wedge, GS Payne, CM Bacon, P Sloan, I Dragoni, ... Clinical Cancer Research 29 (8), 1429-1439, 2023 | 76 | 2023 |
| Oncology phase I trial design and conduct: time for a change-MDICT Guidelines 2022 D Araujo, A Greystoke, S Bates, A Bayle, E Calvo, L Castelo-Branco, ... Annals of Oncology 34 (1), 48-60, 2023 | 65 | 2023 |
Emma DeanDirector Physician, Early Phase Oncology | AstraZenecaPreverjeni e-poštni naslov na astrazeneca.com
